Rentschler Biotechnologie, announced it has successfully transitioned into a European corporation (SE), Rentschler Biopharma SE, with entry into the German commercial register on 1 October, 2017
Rentschler Biotechnologie, a specialist contract development and manufacturing organisation (CDMO) for biopharmaceuticals, will operate as Rentschler Biopharma SE with immediate effect. There will be no operational changes for clients or employees of the family-owned company due to the transition.
Professor Nikolaus F. Rentschler, owner of Rentschler Biopharma SE, said: “With our transition to Rentschler Biopharma SE, we emphasise our long-term international corporate identity, while the core business remains unaffected. In future, this legal form of company strengthens our position as a full-service CDMO and ensures our place as a leader in this industry.
“Our proven service offering along the entire value chain — from bioprocess development through biomanufacturing to fill and finish of biopharmaceuticals — remains unchanged. This also applies to our company sites and manufacturing facilities as well as the existing client relations and importantly their contact persons.”
Recently, Rentschler Biopharma has grown considerably and invested constantly in facilities, its capacity has more than doubled. With the expansion of its facilities, a continually growing number of employees has also been added to the company.
Around 200 employees have been recruited in all business segments during the past year and a half. In the current fiscal year, more than 120 additional positions are to be filled.
Rentschler will present itself as Rentschler Biopharma SE for the first time at the 23rd Annual International Partnering Conference BIO-Europe at booth 42/43.
The conference takes place 6–8 November, 2017 at Messe Berlin.